(34), employing a combination of high-throughput metabolomic and genomic technologies, illuminated that a mutation in NAT8 is associated with N-acetylornithine, N-acetyl-1-methylhistidine, and eGFR, consequently influencing the risk of incident CKD. The gene discussed is NAT8; the disease is chronic kidney disease.